Clinical trials: CD - Crohn's Disease
Crohn Disease
Relationships of B-cell Activating Factor Gene Polymorphisms With Crohn's Disease.
From January 2020 to December 2024, Crohn's disease(CD) patients and gender- and age-matched normal controls were collected from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University.
- Trial name
- NCT07387172
- Where
- China
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Crohn's Disease
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will evaluate the second line effectiveness of upadacitinib and risankizumab in Crohn's Disease (CD) in a real-world…
- Trial name
- CROHNOS (NCT07073079)
- Where
- 25 sites in Italy
- Volunteers
- 250 people
- Sponsor
- AbbVie
Crohn Disease
Effect of SB CD on Chylomicron
It is often suggested that lymphatic vessels are ineffective in transporting cargo in Crohn's disease. Our own work on surgically resected tissue supports this concept (1), but the concept has not been directly tested.
- Trial name
- NCT03496818
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Irritable Bowel Disease, Ulcerative Colitis (UC)
Health-Related Quality of Life Among Patients With Inflammatory Bowel Disease
The primary aim of this study is to assess HRQOL and its associated factors among people with IBD. The target sample will be 385 adult patients diagnosed with IBD (both Crohn's Disease and Ulcerative Colitis).
- Conditions
- Irritable Bowel Disease, Ulcerative Colitis (UC), Crohn Disease (CD)
- Trial name
- NCT07436910
- Where
- Egypt
- Volunteers
- 385 people
- Sponsor
- Cairo University
Inflammatory Bowel Disease, Crohn's Disease
OPERA Database - Crohn's Protocol
The investigators believe that patients with Crohn's disease are able to report details of their own medical history accurately and record changes in clinical status effectively over time.
- Trial name
- OPERA (NCT01720368)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Crohn's Disease
Study for the Treatment of Crohn's Disease With Adacolumn
The purpose of this study is to evaluate the safety and effectiveness of the Adacolumn Apheresis System as a treatment for the signs and symptoms of Crohn's disease.
- Trial name
- NCT00162942
- Testing
- Adacolumn
- Where
- 37 sites in United States, Canada
- Volunteers
- 235 people
- Sponsor
- Otsuka America Pharmaceutical
Crohn Disease
The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )
The purpose of this study is to determine if vitamin D as an adjuvant therapy can improve the outcome (i.e. fewer relapses) and the quality of life, including levels of physical activity, in children diagnosed Crohn's disease…
- Trial name
- ViDiPeC-2 (NCT03999580)
- Testing
- vitamin D3
- Where
- 7 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Jantchou Prevost
Crohn's Disease
Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.
- Trial name
- NCT04002180
- Testing
- Vedolizumab (Genetical Recombination)
- Where
- Japan
- Volunteers
- 335 people
- Sponsor
- Takeda
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
The purpose of this study is to evaluate the efficacy and safety of Ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 306 (NCT03566823)
- Testing
- Ontamalimab
- Where
- 145 sites in United States, Argentina and 18 more
- Volunteers
- 34 people
- Sponsor
- Shire
Anal Fistula
Treatment of Complex Anal Fistulas Using Centrifuged Adipose Tissue Containing Progenitor Cells
In the treatment of complex anal fistulas transplant of freshly collected autologous adipose tissue mechanically fragmented or centrifuged adipose tissue (CAT) might be an alternative to in vitro expanded autologous or allogeneic…
- Trial name
- CAT (NCT04326907)
- Testing
- Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital of Ferrara
Inflammatory Bowel Disease (IBD)
SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
This is an exploratory, open-label, uncontrolled, multi-center, 1-arm study conducted at 16 sites in Bulgaria, Germany and Romania. A total of ca.
- Trial name
- ENTRANCE (NCT00820365)
- Testing
- SC12267 (4SC-101)
- Where
- 16 sites in Bulgaria, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- 4SC AG
Crohn Disease (CD), Ulcerative Colitis (UC)
the REMONO-CD and the REMONO-UC Studies
Infliximab was the first-in-class anti-TNF agent approved for treating patients with IBD, both for Crohn's disease (CD)1 and ulcerative colitis (UC)2.
- Trial name
- REMONO (NCT07564609)
- Where
- 18 sites in France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Clermont-Ferrand
Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease)
The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients
The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1.
- Conditions
- Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
- Trial name
- PIVD (NCT07177157)
- Testing
- Vitamin D3 (Cholecalciferol)
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Terry Ponich
Crohn Disease
The Innate Immune Response and Enteric Nervous System in Crohn's Disease.
The study aims to explore the relationships between inflammation, nerve changes, and the expression of interferon-stimulated proteins in inflamed and non-inflamed bowel areas from patients with Crohn's disease.
- Trial name
- NCT06485193
- Testing
- Immunohistochemistry
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aalborg University Hospital
Crohn's Disease
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab
- Trial name
- NCT00308581
- Testing
- Certolizumab pegol
- Where
- 107 sites in United States, Austria and 12 more
- Volunteers
- 539 people
- Sponsor
- UCB Pharma
Crohn's Disease in Remission
A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease
The goal of this study is to learn about a low sulfur diet in patients with Crohn's disease. Study participants will be randomized to receive a low sulfur diet or usual diet for 8 weeks.
- Trial name
- NCT05849012
- Testing
- Low Sulfur Diet, Usual Diet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Crohn's Disease
Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
Many inflammatory disorders in the body are linked to oxidative tissue damage. Anti-oxidants that are present in many natural food sources may provide protection from such damage.
- Trial name
- NCT00275418
- Testing
- beta carotene from Dunaliella algae
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Bnai Zion Medical Center
Crohn's Disease
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation.
- Trial name
- NCT00048113
- Testing
- Alicaforsen
- Where
- 30 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Crohn Disease
An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease
Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery.
- Trial name
- NCT01090817
- Testing
- Mesenchymal stromal cells (MSC) for infusion
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- R.P.Herrmann
Crohn's Disease
Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study was to demonstrate that tight control of disease activity, using stringent criteria based on Crohn's disease activity Index (CDAI), biomarkers (high sensitivity C-reactive protein [hs-CRP] and…
- Trial name
- CALM (NCT01235689)
- Testing
- Adalimumab, Prednisone, Azathioprine
- Volunteers
- 252 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.